Sinopharm – good grounding

Background:Sinopharm Group (1099:HKG) is China's largest pharmaceuticals and medical device distributor and importer. Retail pharmacy also makes up a small portion (2.6%) of the business through the group's directly operated and franchised pharmacy stores across the country. The group raised $1.13bn through a Hong Kong listing in September last year, yet state-run China National Pharmaceutical Group, the country's largest pharmaceutical conglomerate, remains the largest shareholder. Shanghai Fosun Pharmaceutical (600196:SHA), a unit of Hong Kong-listed conglomerate Fosun International (0656:HKG), also holds a stake in the group.

China Confidential Funds

China Confidential Funds, a new research service launched by FT China Confidential, is dedicated to illuminating the mainland fund industry. Our team of fund industry experts in Shanghai search out the interesting trends in fund performance, strategy, interactions with overseas funds, regulatory changes, distribution and management. We also use a proprietary system to track the emerging flows of Chinese money. Click here to find out more.

Other Articles on this Issue

• Financial China

  Select financial charts

  Defusing time bombs

• Macro View

  A double dip?

• Funds Data

  China flows hold firm

• The Best of Chinese Commentators

  Convergence of interests

  Uncertainties ahead

• The Big Call

  Trade: a profit-poor boom

• Consumer China

  Healthcare services – breaking free from the state

  Topchoice – the only domestic listed dental clinic

  China Nepstar – hostage to state pricing

  Aier – focusing on eye care

• Capital Intensive China

  A slow charge

• Guest Column

  A basket solution

• View issue